erlotinib hydrochloride has been researched along with Adenocarcinoma, Bronchiolo-Alveolar in 37 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 11 (29.73) | 29.6817 |
| 2010's | 26 (70.27) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bury, MJ; Gandara, DR; Hirsch, FR; Kelly, K; Kwong, M; Mack, P; Miao, J; Moon, J; Moore, DF; Nguyen, DD; Redman, M; West, HL; Wozniak, AJ | 1 |
| Bertran-Alamillo, J; Carcereny, E; Costa, C; Gasco, A; Gimenez-Capitan, A; Jimeno, J; Karachaliou, N; Majem, M; Massuti, B; Mayo, C; Molina-Vila, MA; Moran, T; Rosell, R; Sanchez, JJ; Souglakos, J; Viteri, S; Wannesson, L | 1 |
| Chachoua, A; Desai, AM; Garcia-Reglero, V; Marquez-Medina, D; Martin-Marco, A; Muggia, F; Salud-Salvia, A | 1 |
| Aydiner, A; Seyidova, A; Yildiz, I | 1 |
| Bernstein, E; Burrows, F; Gitlitz, BJ; Milne, G; Otterson, GA; Santos, ES; Syto, M; Zaknoen, S | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Antoine, M; Barlesi, F; Bigay-Game, L; Cadranel, J; Friard, S; Gervais, R; Langlais, A; Lethrosne, C; Merle, P; Monnet, I; Moreau, L; Morin, F; Moro-Sibilot, D; Oliviero, G; Quoix, E; Salaun, M; Souquet, PJ; Westeel, V; Wislez, M; Zalcman, G | 1 |
| Argiris, A; Brega, NM; Eaton, KD; Govindan, R; Gutierrez, ME; Ho, SN; Mita, AC; Otterson, GA; Ou, SI; Robert, F; Tan, W; Usari, T | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Camidge, DR; Erickson, TM; Koeppe, JR; Miller, YE; Stuart, RW | 1 |
| Ma, PC; Manson, GV | 1 |
| Neal, JW | 1 |
| English, JF; Erridge, SC; Ironside, JA; Kerr, GR; Little, FA; Mackean, MJ; Price, A | 1 |
| Allan, S; Baliko, Z; Gridelli, C; Heigener, D; Krzakowski, M; Reck, M; Rischin, D; van Zandwijk, N | 1 |
| Fabian, P; Lakomý, R; Nemecek, R; Slabý, O; Stanková, M; Svoboda, M; Vyzula, R | 1 |
| Au, JS; Mok, T; Park, K; Perng, RP; Wu, YL; Zhang, L; Zhou, C | 1 |
| Chattopadhyay, S; Cohen, MH; Johnson, JR; Justice, R; Pazdur, R; Sridhara, R; Tang, S | 1 |
| Cerea, G; Chella, A; Ciardiello, F; de Marinis, F; Di Maio, M; Fasano, M; Favaretto, A; Gridelli, C; Maione, P; Mattioli, R; Morgillo, F; Pasello, G; Ricciardi, S; Rossi, A; Tortora, G | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Agelaki, S; Georgoulias, V; Giassas, S; Kentepozidis, N; Kotsakis, A; Pallis, AG; Papakotoulas, P; Tryfonidis, K; Vamvakas, L; Vardakis, N; Voutsina, A | 1 |
| Cohen, EE; Faoro, L; Gao, F; Govindan, R; Karrison, T; Kozloff, M; Salgia, R; Subramanian, J; Szeto, L; Vokes, EE | 1 |
| Egawa, K; Matsushita, H; Miura, H; Osawa, T; Takahashi, T; Tsubouchi, Y; Yuyama, K | 1 |
| Gasol-Cudós, A; Llombart-Cussac, A; Márquez-Medina, D; Salud-Salvia, A; Samamé Pérez-Vargas, JC; Taberner-Bonastre, MT | 1 |
| El-Modir, A; Stevenson, R | 1 |
| Jappe, A; Jehl, V; Johnson, BE; Klimovsky, J; Papadimitrakopoulou, VA; Soria, JC | 1 |
| Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P | 1 |
| Giuliani, J; Marzola, M | 1 |
| Edelman, MJ | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Al-Hashem, R; Bronson, RT; Chen, L; Chirieac, LR; Jänne, PA; Ji, H; Johnson, BE; Kim, W; Kobayashi, S; Li, D; Mahmood, U; McNamara, K; Mitchell, A; Padera, R; Shapiro, GI; Sharpless, NE; Shimamura, T; Sun, Y; Tenen, D; Weissleder, R; Wong, KK | 1 |
| Arteaga, CL | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Belani, CP; Bonomi, PD; Fehrenbacher, L; Hart, L; Herbst, RS; Lin, M; Melnyk, O; O'Neill, VJ; Ramies, D; Sandler, A | 1 |
| Carbone, DP; Heelan, RT; Heller, G; Herbst, RS; Johnson, DH; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Patel, JD; Riely, GJ; Sandler, AB; Tsao, A; Zakowski, MF | 1 |
4 review(s) available for erlotinib hydrochloride and Adenocarcinoma, Bronchiolo-Alveolar
| Article | Year |
|---|---|
[EGFR tyrosine kinase inhibitors as a targeted therapy for bronchioloalveolar carcinoma of the lung: a case report of a clinically prompt and intensive response and literature review].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGF receptor mutations in lung cancer: from humans to mice and maybe back to humans.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction | 2006 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
13 trial(s) available for erlotinib hydrochloride and Adenocarcinoma, Bronchiolo-Alveolar
| Article | Year |
|---|---|
Paired Phase II Studies of Erlotinib/Bevacizumab for Advanced Bronchioloalveolar Carcinoma or Never Smokers With Advanced Non-Small-cell Lung Cancer: SWOG S0635 and S0636 Trials.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cigarette Smoking; Diarrhea; Drug-Related Side Effects and Adverse Reactions; Erlotinib Hydrochloride; Exanthema; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Survival Analysis; Treatment Outcome | 2018 |
A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cyclooxygenase 2 Inhibitors; Disease Progression; Double-Blind Method; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Prospective Studies; Prostaglandins; Protein Kinase Inhibitors; Pyrroles; Quinazolines; Sulfonamides; Survival Rate | 2014 |
Erlotinib versus carboplatin and paclitaxel in advanced lepidic adenocarcinoma: IFCT-0504.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Carboplatin; Disease-Free Survival; Erlotinib Hydrochloride; Female; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Paclitaxel; Proportional Hazards Models; Treatment Outcome; Young Adult | 2015 |
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Papillary; Crizotinib; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Pyrazoles; Pyridines; Survival Rate; Tissue Distribution | 2017 |
Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; International Agencies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Efficacy and safety of erlotinib in 1242 East/South-East Asian patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Safety; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Approval summary: erlotinib maintenance therapy of advanced/metastatic non-small cell lung cancer (NSCLC).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Double-Blind Method; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2010 |
Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Deoxycytidine; Erlotinib Hydrochloride; Feasibility Studies; Female; Follow-Up Studies; Gemcitabine; Humans; Lung Neoplasms; Male; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Survival Rate; Treatment Outcome | 2011 |
A phase II trial of erlotinib as front-line treatment in clinically selected patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2012 |
Targeted and cytotoxic therapy in coordinated sequence (TACTICS): erlotinib, bevacizumab, and standard chemotherapy for non-small-cell lung cancer, a phase II trial.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate | 2012 |
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; Erlotinib Hydrochloride; Everolimus; Feasibility Studies; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Sirolimus; Tissue Distribution | 2012 |
Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Suppressor of Cytokine Signaling Proteins; Treatment Outcome | 2008 |
20 other study(ies) available for erlotinib hydrochloride and Adenocarcinoma, Bronchiolo-Alveolar
| Article | Year |
|---|---|
BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; BRCA1 Protein; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Endodeoxyribonucleases; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Expression Profiling; Humans; LIM Domain Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Nuclear Proteins; Oligonucleotide Array Sequence Analysis; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Survival Rate; Young Adult | 2013 |
Continued erlotinib maintenance and salvage radiation for solitary areas of disease progression: a useful strategy in selected non-small cell lung cancers?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
Clinical outcomes and prognostic factors associated with the response to erlotinib in non-small-cell lung cancer patients with unknown EGFR mutational status.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2013 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Bronchioloalveolar carcinoma presenting as chronic progressive pulmonary infiltrates in a woman with HIV: a diagnosis worth making.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Chronic Disease; Diagnosis, Differential; ErbB Receptors; Erlotinib Hydrochloride; Female; HIV; HIV Infections; Humans; Lung Diseases, Interstitial; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2008 |
Response to pemetrexed chemotherapy in lung adenocarcinoma-bronchioloalveolar carcinoma insensitive to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Three years of erlotinib in routine practice for non-small cell lung cancer in South East Scotland.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Scotland; Survival Rate; Treatment Outcome | 2010 |
[A case of bronchioloalveolar carcinoma successfully treated with low-dose, alternate-day administration of erlotinib].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2012 |
Human papillomavirus in non-small-cell lung cancer: the impact of EGFR mutations and the response to erlotinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Papillomavirus Infections; Prevalence; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Spain | 2013 |
Unilateral onycholysis in a patient taking erlotinib (Tarceva).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Bronchoscopy; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Onycholysis; Protein Kinase Inhibitors; Quinazolines; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2011 |
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate | 2013 |
The management of skin toxicity during erlotinib in advanced non-small cell lung cancer: how much does it cost?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Eruptions; Erlotinib Hydrochloride; Female; Health Care Costs; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Structure, Tertiary; Quinazolines; Quinolines | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |